Breaking News Bar

Business News and Information

Week in Review: China Life Science Goes International for Deals

Hutchison China MediTech will contribute $50 million to its partnership with AstraZeneca to accelerate global clinical development of savolitinib, a c-MET inhibitor; Ambrx, a San Diego-China biopharma, closed a $45 million financing to underwrite a Phase I trial of a HER2-positive breast cancer treatment; Ornim of Israel raised $20 million from China investors for its non-invasive perfusion measurement medical device; Shangdong Luoxin Pharma in-licensed China rights to a lung cancer drug candidate from South Korea's Yuhan in a $120 million deal; San Diego's Sorrento will form an immuno-oncology joint venture with CHA Biotech of South Korea; Ligand Pharma of San Diego formed a new company to develop three preclinical Ligand programs in China; Ossen Innovation, a Shanghai company, plans to transform itself into a glucose monitoring medical device maker via an acquisition; Chengdu Olymvax Biopharma in-licensed greater China rights to a novel Group A Streptococcus (GAS) vaccine developed by Australia's Griffith University; and ViroMed of South Korea obtained Investigational New Drug approval for its lead gene therapy drug candidate in Korea. More details.... Stock Symbols: (AIM: HCM; NSDQ: HCM) (NYSE: AZN) (HK: 8058) (KSE: 000100) (NSDQ: SRNE) (KOSDAQ: CHA) (NSDQ: LGND) (NSDQ: OSN) (KOSDAQ: 084990) Share this with colleagues: // //  
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear